Capricor's Deramiocel Faces 9-3 AdCom Rejection With FDA Decision Due August 22

The FDA's advisory committee delivered a lopsided verdict on Capricor Therapeutics' Deramiocel on July 29, 2026: 9 against, 3 for, 0 abstaining on whether available evidence supported the therapy's effectiveness for cardiomyopathy in patients with Duchenne muscular dystrophy. The PDUFA target action date is August 22, 2026.

The vote is non-binding. The FDA will weigh the committee's recommendation alongside the full administrative record before issuing its decision.

Piper Sandler expects the FDA to issue another complete response letter rather than approve Deramiocel — a significant signal given the committee's margin.

This is the second time Capricor has been here. In July 2025, the FDA issued a complete response letter stating the application did not provide substantial evidence of effectiveness and flagged outstanding chemistry, manufacturing, and controls issues it said it could not review due to the timing of that CRL. Capricor resubmitted with additional clinical data from the Phase 3 HOPE-3 trial. In March 2026, the FDA lifted the prior CRL and resumed review, classifying the resubmission as a Class 2 resubmission with the August 22 PDUFA date.

The core dispute at the July 29 meeting was statistical methodology. Per FDA briefing documents cited in Capricor's July 30, 2026 press release, the agency contended Deramiocel showed "no statistically significant difference between deramiocel and placebo at 12 months" on HOPE-3's prespecified primary and secondary efficacy endpoints, and that "the results on cardiac imaging parameters taken together are difficult to interpret and do not appear to provide conclusive evidence of a favorable effect of deramiocel on slowing the decline of cardiac function in the studied population." The fight came down to competing statistical analysis plan versions: the FDA relied on an earlier prespecified plan; Capricor asserted that SAP v3.0 was finalized pre-unblinding and should govern interpretation.

Notably, the committee's voting question addressed a narrower indication than Capricor originally proposed and did not include a vote on the therapy's overall benefit-risk profile. In a separate discussion on upper limb function, the committee's feedback was directionally supportive of the Phase 3 HOPE-3 clinical evidence, including results on its primary endpoint — a distinction Capricor will likely press with the FDA before August 22.

CEO Linda Marbán, Ph.D., stated in the company's July 30, 2026 press release: "We are encouraged by the FDA's acknowledgment of our response to the Complete Response Letter and its continued review of our BLA for Deramiocel. We believe the positive HOPE-3 results and broader clinical evidence reinforce Deramiocel's potential to become a first-in-class therapy for Duchenne muscular dystrophy, with the opportunity to address both skeletal and cardiac manifestations of the disease."

On the balance sheet, Capricor holds $278.61 million in cash against $14.78 million in debt, a net cash position of $263.83 million or $4.56 per share, per StockAnalysis data as of August 3, 2026. Per WallStreetZen accessed around August 3, 2026, the company has 57,911,893 shares outstanding and a market capitalization of $242.65 million at $4.19 per share — figures that sit alongside a net cash position of $4.56 per share, according to those respective sources.

No approved treatment currently exists for DMD cardiomyopathy. That unmet need has driven Capricor's case throughout the review process, but the FDA's own briefing documents and a 9-3 committee vote indicate the agency's efficacy bar remains uncleared as of the July 29 meeting.

The FDA's decision is due August 22, 2026.